These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on February 20, 2013.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $34.04 to $34.51.
Includes 10,000 restricted stock units awarded January 27, 2011, of which 1/3 of the shares vest on February 15, 2014, and the 1/3 of the shares that vested on each of February 15, 2012 and 2013, net of withholding.
Includes 10,000 restricted stock units awarded February 5, 2012, of which 1/3 vest on each of February 15, 2014 and 2015 and the 1/3 of the shares that vested on February 15, 2013, net of withholding.
Includes 9,000 restricted stock units awarded July 25, 2013, of which 1/3 of the shares vest on each of February 15, 2014, 2015 and 2016.
The option became exercisable as to 25% of the shares on December 2, 2005, and becomes exercisable as to 1/48th of the shares each full month thereafter.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever Genomic Health makes a similar move, sign up!
Other recent filings from the company include the following:
Genomic Health's CFO just cashed-in 3,000 options - Dec. 10, 2013